Regeneron

News

A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron.

Oncology

News

23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.

News

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

News

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.